Pharmacophore-based virtual screening for identification of marine sponge bioactive compound inhibitors against Alzheimer's disease

• Pipeline for In-silico screening of bulk compounds. • Repurposing of bioactive compounds against alzheimer's disease. • Exploration of novel secondary metabolite from marine source which are yet to be validated. • Intercorrelation of AchE, GABA, serotonin and TrkB signalling pathway. Alzheimer's disease is a hereditary neurodegenerative disease that occurs sporadically and causes amnestic cognitive impairment. Traditional drug discovery methods have faced challenges in this regard, leading researchers to explore natural products as potential therapeutics. Marine sponges are rich in diverse range of bioactive compounds with promising biological activities. In this study, AChE, SLC6A4, 5-HT1A, TrkB, and GABA are chosen as the target proteins, which focuses on ache, serotonin, GABA, and neurotropic pathways. A bioactive compound library from marine sponges was prepared by retrieving a list from the CMNP database. The compounds were screened using a chronological index and Drug likeness rules where 2,504 compounds were filtered out based on their molecular weight and the selected compounds undergone secondary screening using pharmacology filters to assess their absorption, distribution, metabolism, and excretion (ADME) properties. Virtual screening was performed using PyRx with selected target proteins. Four compounds namely Xestosaprol D, Xestosaprol E, Xestosaprol J, and 14, 15-dihydroxymethyl Xestoquinone were found to interact with all the chosen protein. Among 4 compounds, Xestosaprol J showed better binding energy of -7.7, -9.9, -8.4, -9.2, and -8.1 kcal/mol. Further, the best interacting AchE-Xestosaprol J complex along with standard AchE Agonist Donepezil was subjected to Molecular dynamics simulation and analysis, which maintained its stability between 65 and 85 ns with RMSD value ranging between 0- 3.5 Å in the virtual biological environment. Overall, Xestosaprol J showed better physicochemical and ADME properties, suggesting their potential as drug candidates, but further investigations are needed to determine their specific biological activities in-vitro .

Authors

Institutions

Publication Details

Journal
Chemical Physics Impact
Published
2024-12-28
DOI
https://doi.org/10.1016/j.chphi.2024.100805
Citations
3
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
1.08
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pharmacophore-based virtual screening for identification of marine sponge bioactive compound inhibitors against Alzheimer's disease

Suruthi SS, A Baskaran, Prashanth KK
3 citations
Chemical Physics Impact
Computational Drug Discovery Methods
1.08
article

Pharmacophore-based virtual screening for identification of marine sponge bioactive compound inhibitors against Alzheimer's disease

Suruthi SS, A Baskaran, Prashanth KK
article en
3 citations

Abstract

• Pipeline for In-silico screening of bulk compounds. • Repurposing of bioactive compounds against alzheimer's disease. • Exploration of novel secondary metabolite from marine source which are yet to be validated. • Intercorrelation of AchE, GABA, serotonin and TrkB signalling pathway. Alzheimer's disease is a hereditary neurodegenerative disease that occurs sporadically and causes amnestic cognitive impairment. Traditional drug discovery methods have faced challenges in this regard, leading researchers to explore natural products as potential therapeutics. Marine sponges are rich in diverse range of bioactive compounds with promising biological activities. In this study, AChE, SLC6A4, 5-HT1A, TrkB, and GABA are chosen as the target proteins, which focuses on ache, serotonin, GABA, and neurotropic pathways. A bioactive compound library from marine sponges was prepared by retrieving a list from the CMNP database. The compounds were screened using a chronological index and Drug likeness rules where 2,504 compounds were filtered out based on their molecular weight and the selected compounds undergone secondary screening using pharmacology filters to assess their absorption, distribution, metabolism, and excretion (ADME) properties. Virtual screening was performed using PyRx with selected target proteins. Four compounds namely Xestosaprol D, Xestosaprol E, Xestosaprol J, and 14, 15-dihydroxymethyl Xestoquinone were found to interact with all the chosen protein. Among 4 compounds, Xestosaprol J showed better binding energy of -7.7, -9.9, -8.4, -9.2, and -8.1 kcal/mol. Further, the best interacting AchE-Xestosaprol J complex along with standard AchE Agonist Donepezil was subjected to Molecular dynamics simulation and analysis, which maintained its stability between 65 and 85 ns with RMSD value ranging between 0- 3.5 Å in the virtual biological environment. Overall, Xestosaprol J showed better physicochemical and ADME properties, suggesting their potential as drug candidates, but further investigations are needed to determine their specific biological activities in-vitro .

Chemical Physics ImpactVol. 10
Scientific Services (ZA), B.S. Abdur Rahman Crescent Institute of Science & Technology (IN)
Life below water
Openalex Percentile: Top 19%
Computational Drug Discovery Methods
1.08
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.